Nektar TherapeuticsNKTRNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank7
3Y CAGR-18.7%
5Y CAGR-22.1%
Year-over-Year Change
Research and development spending
3Y CAGR
-18.7%/yr
vs -14.0%/yr prior
5Y CAGR
-22.1%/yr
Recent acceleration
Acceleration
-4.7pp
Decelerating
Percentile
P7
Near historical low
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $117.33M | -3.0% |
| 2024 | $120.91M | +5.9% |
| 2023 | $114.16M | -47.7% |
| 2022 | $218.32M | -45.5% |
| 2021 | $400.27M | -2.1% |
| 2020 | $408.68M | -6.0% |
| 2019 | $434.57M | +8.8% |
| 2018 | $399.54M | +48.8% |
| 2017 | $268.46M | +31.7% |
| 2016 | $203.80M | - |